Background/Aim: Hyperthermia (HT), combined with chemotherapy, has been used to treat various types of cancer. This study aimed to investigate the HT-sensitivity of malignant and non-malignant cells, and then evaluate the combination effect of docetaxel (DTX) and a newly synthesized chromone derivative (compound A) with HT. Materials and Methods: The number of viable cells was determined using the MTT method. Cell cycle distribution was analyzed using a cell sorter, and DNA fragmentation pattern was detected using agarose gel electrophoresis. Results: Among 12 cultured cells, oral squamous cell carcinoma (OSCC), especially Ca9-22 cells, and myelogenous leukemia cells showed higher sensitivity to HT than lung carcinoma and glioblastoma cell lines, while normal oral cells were the most resistant.
Cytotoxicity of DTX on Ca9-22 cells was maximum at 41-42˚C and 45~60 min exposure to HT. DXT, compound A, and HT induced G 2 /M arrest of Ca-22 cells. Mild HT enhanced the DTX-and compound A-induced subG 1 arrest, in a synergistic fashion. Conclusion: The combination G 2 /M blockers and mild-HT can potentially be used for the treatment of OSCC.Surgery, radiation, and chemotherapy are three standard treatments for oral cancer. Considering the postoperative impairment of physical function and appearance, minimally invasive therapies such as chemotherapy combined with hyperthermia (HT), which induces cancer cell death by heating to 42.5˚C or higher (1, 2), are promising. Treatment of malignant tumors with HT in Japan has long track record since the approval of insurance coverage in 1990. While chronic myelogenous leukemia cells have been reported to be highly sensitive to HT (3,4), clinical reports of HT on oral cancer have been limited. For HT, cancerous tissue is placed between two electrodes, and then is exposed to Joule heat generated using the radiofrequency dielectric warming method. This method is applicable to breast cancer that can be easily clamped between the electrodes, but not to primary tumor such as oral cancer (especially tongue cancer, which moves involuntarily). Therefore, HT for head and neck cancer, including oral cancer, is generally applied to cervical lymph node metastasis rather than the primary tumor (5). We have reported favorable clinical data of superselective intraarterial chemoradiotherapy (based of cisplatin, docetaxel (DTX) and radiation) for patients with oral squamous cell carcinoma with lymph node metastasis (6). In addition to the direct application to tumor, combination of relatively lower temperature for HT (41-42˚C) [mild hyperthermia (mild-HT)] have been reported (7, 8).